We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · November 23, 2022

UCART19, a First-in-Class Allogeneic Anti-CD19 CAR T-Cell Therapy, for Adults With Relapsed/Refractory B-ALL

The Lancet Haematology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Haematology
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
Lancet Haematol 2022 Nov 01;9(11)e833-e843, R Benjamin, N Jain, MV Maus, N Boissel, C Graham, A Jozwik, D Yallop, M Konopleva, MJ Frigault, T Teshima, K Kato, F Boucaud, S Balandraud, A Gianella-Borradori, F Binlich, I Marchiq, S Dupouy, M Almena-Carrasco, M Pannaux, S Fouliard, E Brissot, M Mohty

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading